Abaniki bomhlaza besifo se-Breast bangama-molecule athile aveliswa kumzimba wabasetyhini njengempendulo yomhlaza kunye nakwezinye iimeko. Ukuba izinga labamachiza bomhlaza liphezulu kunelo liqhelekileyo, oko kungabonisa ukuba kukho inkqubo yomhlaza. Ngaphandle koqhagamshelwano, kunzima ukwenza kokubili ukuxilongwa kunye nokubeka esweni izifo ezinxulumene ne-oncology. Ngokuqhelekileyo ukuxilongwa kwangaphambili komhlaza wesifuba kwenziwa ngokuchanekileyo ngenxa yezimpawu zobumnyama.
Abaveleli bomhlaza wesibeleko bajikeleza egazini. Inani labo alimele lidlulele kwisiqhelo. Nangona kunjalo, ukuba izinga labo liphakanyisiwe, oku akuthethi rhoqo ukuba kukho utshintsho olungenakuguquka kwiiseli. Ngokuqhelekileyo, isiphumo esiphumeleleyo sinokubangelwa kubukho bomsindo, isifo se-pancreas, isibindi kunye neentso. Nangona kunjalo, kuzo zonke iimeko, xa umakishi womhlaza wesifuba unyuka, kubalulekile ukuba ufumane iimviwo ezongezelelweyo ukuba akhiphe umhlaza.
CA 15-3
Iimpawu zamathambo zikhona ngeendlela ze-antigens, i-enzyme, i-hormone kunye nama-proteins. Amanqaku ahlukeneyo akhiqizwa ngeentlobo ezahlukeneyo zezihlamba. Ngomdlavuza wesifuba uthi izinga eliphakamileyo lommakethi CA 15-3 (i-antigen ethile). Icandelo leenkcukacha zalo lifikelela kuma-95% ekuxilongeni kwebele ye-carcinoma xa kuthelekiswa nezicubu ezinobungozi, apho zingaphakanyiswa khona.
Ummakishi we-tumor CA 15-3 kwiinkcenkceshelo zaso ngokulinganayo ngokulinganayo nobukhulu besisu. Kwakhona, ixabiso layo eliphakamileyo linokubonisa ukuba i-lymph nodes zibandakanyeka kwinkqubo ye-oncology. Ukuqaphela izinga lalo mhlaba uvumela ukuba ulandele ngokuchanekileyo indlela inkqubo eqhubeka ngayo, nokuba ingaba unyango lusebenzayo. Kungenxa yesi sizathu ukuba uhlalutyo olulodwa lubekwe ngokuthe gqolo kunokuba luhlalutye kwizinto ezinamandla. Kucatshangelwa ukuba ukuba lo mmakishi uphuma kwi-serum yegazi ngo-25%, eso sifo siyaqhubeka. Ukuba izinga lalo liyehliswa ngokukhawuleza, ngoko unyango lubhekwa njengolusebenzayo.
Ukongeza, ummakishi we-AC 15-3 uhlala ehlolwe xa ubeka iliso ekubunjweni kwemitha yesifo kunye nokubuyela kwakhona. Nangona kunjalo, emva kwe-chemotherapy okanye i-radiotherapy, kunye nokusetyenziswa komntu ngamnye, inqanaba layo liyakhula okwesikhashana. Oku kubonisa ukuba i-tumor iyatshatyalaliswa.
Kukho ubungqina bokuba ngexesha lokukhulelwa, inqanaba le-CA 15-3 livame ukunyuka, okungekho uphawu lomhlaza.
CA 15-3 no-REA
Ukucacisa ngokuchanekileyo ubukho kunye nokulandelelana kokuphuhliswa kwesisu, kucetyiswa ukuba uphando kwinqanaba labanye abamakhwala. Ngokuqhelekileyo, i-CA 15-3 ivavanywa ngokubambisana ne-REA (i-anti-cancer embryonic antigen), eyimpawu zamathambo e-rectum.
Abaniki bomhlaza wesibindi:
Umgangatho we-CA 15-3 uvela kwi-0 ukuya ku-22 U / ml. Njengomthetho, ukukhubazeka kungafunyanwa xa ingcamango ingaphezu kwama-30 U / ml. Ngokwezibalo, kwi-80% yezigulane ukwanda kwinqanaba lommakishi lomhlaza kubonisa inkqubo yokumelana nomhlaza.
Ukuba uthatha uhlalutyo lwabaqeshi beengqambela zomhlaza, isicatshulwa kufuneka senziwe kuphela ngugqirha. Njengomthetho, ukuxilongwa akukwenziwe kwisiseko sokubona kuphela i-hung ye-offcomers. Kubalulekile ukuqhuba uphando olubanzi lweengxelo ukuqinisekisa ubungqina be-oncology.
Ungesabi ukuvavanya, kuba i-98% yeziganeko zomhlaza wesifuba ziphela ekunyangeni okupheleleyo, ukuba ukuxilongwa kufike ngexesha kwaye kuchanekile.